Phase 2 Study of Sitagliptin in Glioblastoma Patients to Enhance Immune Response
A Phase 2 study is evaluating sitagliptin's potential to improve immune response in glioblastoma patients by targeting MDSCs.
Asset / Drug
Drug and asset intelligence for Sitagliptin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.